Drug Trial Radar · NCT05383742
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
330
Planned (sponsor's estimate)
Start
Dec 7, 2023
Primary completion
Oct 1, 2029
Study completion Mar 5, 2030
Sponsor
- Sponsor type
- NIH
- First posted
- May 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare a 6-month regimen of high-dose rifampicin (RIF), high-dose isoniazid (INH), linezolid (LZD), and pyrazinamide (PZA) versus the World Health Organization (WHO) standard of care (SOC) treatment for tuberculosis meningitis (TBM).
Conditions
- Tuberculous Meningitis
Interventions
Rifampicin (RIF)Drug
Rifampicin 35 mg/kg
Isoniazid (INH)Drug
Isoniazid 10 or15 mg/kg
Linezolid (LZD)Drug
1200 mg
Pyrazinamide (PZA)Drug
25 mg/kg
ethambutol (EMB)Drug
20 mg/kg
RifampicinDrug
10 mg/kg
IsoniazidDrug
5 mg/kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified Rankin Scale (6-death, 5-severe disability, 4-moderately severe disability, 3-moderate disability, 2-slight disability, 1-no significant disability, 0-no symptoms)Time frame: At 48 weeks
Locations
18 sites in 12 countries. Site status is shown where the registry gives one.
Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS (Site ID: 12201)
Porto Alegre, Brazil · Recruiting
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101)
Rio de Janeiro, Brazil · Recruiting
Byramjee Jeejeebhoy Government Medical College (BJMC) CRS (Site ID: 31441)
Pune, India · Recruiting
Moi University Clinical Research Center (MUCRC) CRS (Site ID: 12601)
Eldoret, Kenya · Recruiting
Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS (Site ID: 12501)
Kericho, Kenya · Recruiting
Malawi CRS (Site ID: 12001)
Lilongwe, Malawi · Recruiting
Nutrición-Mexico CRS (Site ID: 32078)
Mexico City, Mexico · Not yet recruiting
Barranco CRS (Site ID:11301)
Lima, Peru · Not yet recruiting
Socios En Salud Sucursal Peru CRS (Site ID: 31985)
Lima, Peru · Not yet recruiting
TB HIV Innovations and Clinical Research Foundation Corp (Site ID: 31981)
Cavite, Philippines, Philippines · Not yet recruiting
Durban International Clinical Research Site CRS (Site ID:11201)
Durban, South Africa · Not yet recruiting
Wits Helen Joseph Hospital CRS (Wits HJH CRS) (Site ID: 11101)
Johannesburg, South Africa · Recruiting
Kilimanjaro Christian Medical Centre (KCMC) (Site ID: 5118)
Moshi, Tanzania · Not yet recruiting
Chiangrai Prachanukroh Hospital NICHD CRS (Site ID: 5116)
Chiang Mai, Thailand · Recruiting
Siriraj Hospital, Mahidol University NICHD CRS (Site ID: 5115)
Bangkok, Bangkoknoi, Thailand · Not yet recruiting
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802)
Bangkok, Pathumwan, Thailand · Not yet recruiting
National Lung Hospital CRS (Site ID: 32483)
Vĩnh Phúc, Hanoi, Vietnam · Recruiting
Milton Park CRS (Site ID: 30313)
Harare, Zimbabwe · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.